EBR Systems Advances Towards FDA Approval for WiSE® System

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:EBR) has released an update.

Pick the best stocks and maximize your portfolio:

EBR Systems, Inc., the creator of the innovative WiSE® CRT System for heart failure, has scheduled a crucial Pre-Approval Inspection with the FDA for early January 2025. This milestone is part of the ongoing review of their Pre-Market Approval submission, which could pave the way for their unique wireless cardiac pacing device to hit the market. The inspection will ensure that EBR’s manufacturing processes meet regulatory standards, further advancing this breakthrough technology through the approval process.

For further insights into AU:EBR stock, check out TipRanks’ Stock Analysis page.

Trending Articles

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.